Development of Masitinib Derivatives with Enhanced M(pro) Ligand Efficiency and Reduced Cytotoxicity

Recently, a high-throughput screen of 1900 clinically used drugs identified masitinib, an orally bioavailable tyrosine kinase inhibitor, as a potential treatment for COVID-19. Masitinib acts as a broad-spectrum inhibitor for human coronaviruses, including SARS-CoV-2 and several of its variants. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Menendez, Cintia A., Mohamed, Adil, Perez-Lemus, Gustavo R., Weiss, Adam M., Rawe, Benjamin W., Liu, Guancen, Crolais, Alex E., Kenna, Emma, Byléhn, Fabian, Alvarado, Walter, Mendels, Dan, Rowan, Stuart J., Tay, Savaş, de Pablo, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536273/
https://www.ncbi.nlm.nih.gov/pubmed/37764425
http://dx.doi.org/10.3390/molecules28186643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536273/
https://www.ncbi.nlm.nih.gov/pubmed/37764425
http://dx.doi.org/10.3390/molecules28186643

Ejemplares similares